Results
acute kidney injury, nephropathy
NEPHROPATHY
A total of 310 were assessed for eligibility and 244 patients meet our inclusion criteria. Of the 244 patients randomized, 31 patients lost follow-up visits and are excluded from final analysis as shown in CONSORT flowchart (Fig. CONSORT flowchartBaseline patients’ characteristicsThe baseline median (interquartile range “IQR”) serum creatinine was 0.80 (0.60, 0.98) mg/dl in placebo group and 0.80 (0.60, 1.00) mg/dl in statin plus ascorbic acid group with insignificant The final median (interquartile range “IQR”) serum creatinine were 0.80 (0.60, 1.00) mg/dl in placebo group and 0.80 (0.60, 1.00) mg/dl in statin plus ascorbic acid group, with insignificant Baseline and final patients renal profile characteristicsBaseline serum creatinine, mg/dlMedian (IQR)Final serum creatinine, mg/dlMedian (IQR)Baseline estimated GFR, mL/minMedian (IQR)Final estimated GFR, mL/minMedian (IQR)Bold indicates statistical significanceThe estimated GFR difference median (IQR) were − 6.46 (− 11.72, − 4.18) and − 6.57 (− 13.38, − 3.82) ml/min in placebo and statin plus ascorbic acid groups, respectively, with insignificant Regarding the contrast medium-induced nephropathy, defined in this trial by increase serum creatinine by 0.3 mg/dl, it occurred in 11 patients (9.8%) in placebo group and in 3 patients (3%) in statin plus ascorbic acid group, with statistical significant Boxplot graph for the comparison between patients with and without acute kidney injury, regarding baseline (Compared to the patients baseline values, in the placebo group, the mean ± SD serum creatinine rise from 0.80 ± 0.22 0.82 ± 0.24 mg/dl (The same occurred in the statin plus ascorbic acid group, compared to the its baseline values, the mean ± SD serum creatinine rise from 0.80 ± 0.21 to 0.81 ± 0.23 mg/dl (Final patients renal profile characteristics, compared to their baseline profileBold indicates statistical significance